Natriuretic peptide [NP; B‐type NP (BNP), N‐terminal proBNP (NT‐proBNP), and
midregional proANP (MR‐proANP)] concentrations are quantitative plasma biomarkers for …

Background and Purpose: Natriuretic peptides have led the way as a diagnostic and
prognostic tool for the diagnosis and management of heart failure (HF). More recent …

2021 Update to the 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart
Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection …

Importance In patients with heart failure and reduced ejection fraction (HFrEF), treatment
with sacubitril-valsartan reduces N-terminal pro–b-type natriuretic peptide (NT-proBNP) …

Abstract The 2017 ACC/AHA/Heart Failure Society of America (HFSA) heart failure (HF)
guidelines (1) reflect a focused update of the ACC/AHA 2013 HF guidelines (2) and include …

Heart failure (HF) is a complex syndrome with an enormous societal burden in terms of cost,
morbidity, and mortality. Natriuretic peptide testing is now widely used to support diagnosis …

Aims Significant efforts are currently undertaken to reduce functional mitral regurgitation
(FMR) in patients with chronic heart failure in the hope to improve prognosis. We aimed to …

Heart failure is a global public health problem that affects more than 26 million people
worldwide. The global burden of heart failure is growing and is expected to increase …

Background: Soluble suppression of tumorigenesis-2 (sST2) is a biomarker related to
inflammation and fibrosis. Objectives: This study assessed the independent prognostic value …

Despite the enhanced knowledge of the pathophysiology of heart failure (HF), it still remains
a serious syndrome with substantial morbidity, mortality, and frequent hospitalizations …